PDF
XLS
DOC
DOC
Johnson & Johnson Pricing Transparency Report
View report
Our R&D investments
Drug list prices
Rebates, discounts & fees
Affordable access
The 340B program
Valuing pharmaceuticals in the U.S.
What we believe
Citations
Read full report
Fast facts
2023 at a glance
$42.8 Billion: breaking it down
Rebates, discounts and fees
Watch: 2023 Transparency Report
PDABs and UPLs
The 340B program
Archive
Menu
Archive
View report
Our R&D investments
Drug list prices
Rebates, discounts & fees
Affordable access
The 340B program
Valuing pharmaceuticals in the U.S.
What we believe
Citations
Read full report
Fast facts
2023 at a glance
$42.8 Billion: breaking it down
Rebates, discounts and fees
Watch: 2023 Transparency Report
PDABs and UPLs
The 340B program
Archive Page
Summbit
October 30, 2024
2023 U.S. pricing transparency report
September 30, 2024
Letter in Response to HRSA
September 20, 2024
Johnson & Johnson Rebate Model summary letter
September 20, 2024
12 things to know about J&J’s 340B Rebate Model Policy
Influence of PDABs and UPLs on the State Drug Pricing Ecosystem
2022 Janssen Transparency Report
May 25, 2023
How Insurers Divert Co-Pay Support Meant for Patients
May 25, 2023
The 340B Program
2021 Janssen U.S. Transparency Report
2020 Janssen US Transparency Report Executive Summary
2020 Janssen US Transparency Report
2016 Janssen US Transparency Report Executive Summary
2016 Janssen US Transparency Report
2017 Janssen US Transparency Report Executive Summary
2017 Janssen US Transparency Report
2018 Janssen US Report Executive Summary
2018 Janssen US Transparency Report
April 1, 2019
2019 Janssen US Transparency Report Executive Summary
April 1, 2019
Janssen 2019 Transparency Report
